Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Teijin Pharma Forecasts Major Growth in 2005, 2006
October 6, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 6, 2003
-
ARCHIVE 1st Drug Therapy for Internal Hemorrhoids Expected in FY2004: Lequio, MPC
October 6, 2003
-
ARCHIVE Takara Bio Develops High Precision Monitoring Method for Inserted Genes
October 6, 2003
-
ARCHIVE PBI to Begin Full-scale Contract Manufacture of Antibody Drugs
October 6, 2003
-
ARCHIVE RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 6, 2003
-
ARCHIVE Physicians Trust Viagra Based on Evidence: Pfizer
October 6, 2003
-
ARCHIVE PRESS SEMINAR
October 6, 2003
-
ARCHIVE AnGes MG Pursuing Alliance Strategy: Prof. Morishita
October 6, 2003
-
ARCHIVE Otsuka: WATER (18O, 95%) CIL for PET
October 6, 2003
-
ARCHIVE New Relief Measures Planned for Developing Countries: JPMA
October 6, 2003
-
ARCHIVE Japanese Healthcare Q&A (1)
October 6, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 6, 2003
-
ARCHIVE WEBSITE NEWS
October 6, 2003
-
ARCHIVE Chuikyo Starts Discussion to Review NHI Pricing Rule
October 6, 2003
-
ARCHIVE Sanwa Kagaku Kenkyusho: Glutest Neo Blood Glucose Meter
October 6, 2003
-
ARCHIVE PFSB to Beef Up NDA Review, Safety Measures, Victim Relief via New Drug Organization
October 6, 2003
-
ARCHIVE BULLETIN
October 6, 2003
-
ARCHIVE Revisions of Package Inserts Required for 16 Drugs, Including Ribavirin
October 6, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
October 6, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…